CD38-Directed Antibody for the Treatment of Appropriate Relapsed Refractory Multiple Myeloma Patients
Thursday, June 25
5:00 PM PT
Participants of this live discussion will be able to:
-
Learn about the indication, mechanism of action, and important safety information for Sarclisa (isatuximab-irfc)
-
Gain in-depth knowledge on clinical data in adult patients with relapsed refractory multiple myeloma
-
Understand the dosage and administration of Sarclisa.
-
Learn about support available for eligible patients treated with Sarclisa.
For registration information or to learn more, click here.
Posted 6/25/2020